An offering statement regarding this offering has been filed with the U.S. Securities and Exchange Commission (the “SEC”). The SEC has qualified that offering statement, which only means that the company may make sales of the securities described by the offering statement. The offering circular that is part of that offering statement is available here. 

This Regulation A+ offering is made available through Digital Offering, LLC. This investment is speculative, potentially illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

The securities offered by Daré Bioscience Inc.  (“Daré”) are highly speculative. Investing in these securities involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Investors must understand that such investment could be illiquid for an indefinite period of time. There is no existing public trading market for the Series A Preferred Stock or the related common stock purchase warrants. Daré does not intend to apply for listing of the Series A Preferred Stock or the common stock purchase warrants on a national securities exchange or to be quoted on an over-the-counter market.

Significant risk factors include: i) inability to raise additional capital or generate sufficient revenues to fund operations, ii) inexperience as a company and lack of infrastructure for commercializing products, iii) failure to complete development or obtain FDA or foreign regulatory approval for certain product candidates, iv) degree of market acceptance by any product and v) weak interest in women’s health relative to other healthcare sectors.  Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.

Digital Offering, member FINRA/SIPC is the broker-dealer of record for this offering.

The securities being offered by Daré are not being offered to the residents of any jurisdiction in which such an offer is unauthorized or unlawful.

The investor perks are subject to terms and conditions, including that Daré reserves the right to modify, substitute, or discontinue any perk at its discretion; investor perks are non-transferable unless otherwise noted and may be subject to additional eligibility or participation requirements at the time of fulfillment. For additional information regarding the investor perks, including their terms and conditions, see the section titled “Investor Perks” under “Plan of Distribution” in the offering circular available here.

This website and the information presented herein may include “forward-looking statements” about Daré’s business strategy, plans, objectives and prospects, financial and operating performance, collaborations, intellectual property, products and investigational products. All statements, other than statements of historical fact are forward-looking statements. In some cases, forward-looking statements may be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “upcoming,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “positioned,” “pursue,” “seek,” “should,” “would,” “project,” “target,” “explore” “goal,” “on track,” or the negative version of these words and similar expressions. Forward-looking statements reflect management’s estimates and expectations based on current information and involve significant risks, uncertainties and assumptions. If underlying assumptions prove to be incorrect or known or unknown risks materialize, Daré’s actual results, performance or achievements may differ materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, without limitation, those related to: sufficiency of and ability to obtain additional capital to fund operations and execute Daré’s business strategy; Daré’s inexperience, as a company, in and lack of infrastructure for commercializing products; dependence on third parties over which Daré has limited or no control to conduct research and development activities, including clinical trials, manufacture products and investigational products, and commercialize products, and the risk that those third parties will not perform as required or expected; difficulties and delays in establishing and maintaining third-party collaborations; delays and disruptions in manufacturing products or investigational products, including due to supply chain disruptions; market demand for and acceptance of products; developments by competitors that make Daré’s products less competitive or obsolete; shifts in consumer spending or behavior; challenges and uncertainties inherent in new product research and development, including clinical trials, including the timing and costs thereof; decisions by regulatory authorities, including the U.S. Food and Drug Administration (FDA), regarding whether, when and on what conditions to approve or clear applications and other submissions relating to product development and marketing approval; changes in laws, regulations or regulatory guidance that impact Daré’s ability to bring proprietary solutions to market as compounded drug products under Section 503B of Federal Food, Drug, and Cosmetic Act or as consumer health products or to seek and obtain FDA approval of investigational products utilizing the regulatory pathway known as the FDA’s 505(b)(2) pathway, or that affect the pharmaceutical or health care industry; Daré’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré’s and its licensors’ ability to obtain and maintain sufficient intellectual property protection; product access, coverage, pricing and reimbursement; product recalls; governmental investigations, actions or proceedings; litigation and legal proceedings, including product liability or intellectual property claims and actions; cybersecurity incidents or similar events that compromise Daré’s technology systems and/or significantly disrupt Daré’s business or those of third parties on which it relies; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations; and Daré’s ability to maintain compliance with Nasdaq’s continued listing requirements and continue to have its common stock listed on The Nasdaq Capital Market. For a detailed discussion of factors that could cause Daré’s actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements, you are encouraged to review Daré’s filings with the U.S. Securities and Exchange Commission, including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q, which are available via the “Investors” page at https://staging-daremain.wordkeeper.net and at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they are made regardless of the date on which you view them on this website or elsewhere. Daré assumes no obligation to update any forward-looking statements as a result of new information, future events or otherwise, except as may be required by law.

By accessing this site and any pages on this site, you agree to be bound by our Terms of Service and Privacy Policy, as may be amended from time to time without notice or liability.